Lyra Therapeutics, Inc.
LYRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -86.3% | 0% | -12.4% | – |
| Gross Profit | -$0 | -$0 | $0 | $0 |
| % Margin | -300% | -9.3% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -23,524% | -3,953.6% | -4,277.6% | -4,600.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -23,936% | -4,063.9% | -4,670.5% | -5,253.1% |
| EPS Diluted | -3.38 | -5.51 | -0.13 | -0.17 |
| % Growth | 38.7% | -4,138.5% | 23.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |